The US Food and Drug Administration (FDA) is reminding health care professionals who prescribe and dispense antibiotics that there are recent safety labeling changes for systemic fluoroquinolones.
The US Food and Drug Administration (FDA) is reminding health care professionals who prescribe and dispense antibiotics that there are recent safety labeling changes for systemic fluoroquinolones. The purpose of the new prescribing information is to strengthen and clarify previous label warnings about the risks for serious blood sugar disturbances and psychiatric side effects associated with these medications. The changes are summarized below:
In July 2018, the FDA issued a
(DSC) providing detailed information that supports the issue of new safety labeling changes.
The DSC also advises practitioners to alert patients of the symptoms of hypoglycemia, to carefully monitor these patient’s blood glucose levels, and to discuss with them what to do if they have symptoms of hypoglycemia. Based on this DSC, we are also advising practitioners to inform patients about the risk of psychiatric adverse reactions that can occur after just one fluoroquinolone dose. Patients should immediately stop fluoroquinolone treatment if they experience central nervous system side effects, including any of the psychiatric adverse reactions. If blood glucose disturbances arise, the FDA advises a switch to a nonfluoroquinolone antibiotic, if possible. Pharmacists should be aware that the FDA advises prescribers to stop fluoroquinolone treatment immediately and switch their patient to a nonfluoroquinolone antibiotic if he or she reports serious side effects involving the tendons, muscles, joints, or nerves.
When dispensing any fluoroquinolone, it’s important for pharmacists to remember that the FDA also requires that patients receive a
to inform them about the risks from the medication, which is required at the time of dispensing. Pharmacists are encouraged to explain the importance of the Medication Guide to patients. FDA’s labeling changes also apply to the medication guides for the entire class of fluoroquinolones. The FDA strongly encourages pharmacists to talk with patients about these potential risks.
In July 2016, FDA issued a drug safety communication and required labeling changes for fluoroquinolones warning about their association with disabling and potentially permanent side effects of the tendons, muscles, joints, nerves, and central nervous system that can occur together in the same patient.
As a result, for all fluoroquinolones, the FDA required a change to the FDA's strongest warning, a
and other labeling changes, including changes to the patient Medication Guide.
These recent safety issues mark another reminder for pharmacists of the known adverse effects that can occur in patients treated with fluoroquinolones. These latest warnings in the new labeling add to other risks of phototoxicity, nephrotoxicity, seizures and other CNS disturbances, tendonitis, gastrointestinal effects, prolonged QTc interval and torsade de pointes, and hypersensitivity reactions. Pharmacists are strongly encouraged to be selective when recommending the use of fluoroquinolones and to consider alternative agents when possible. Since 2016, the FDA has advised that the serious risk of side effects associated with fluoroquinolone antibacterial drugs generally outweigh the benefits for patients with acute sinusitis, acute bronchitis, and uncomplicated urinary tract infections who have other treatment options—and that for patients with these conditions, fluoroquinolones should be reserved for those who do not have alternative treatment options.
As a reminder, the group of fluoroquinolones affected by these labeling changes are the systemic (injection and oral) preparations of levofloxacin (Levaquin), ciprofloxacin (Cipro and Cipro extended release), moxifloxacin (Avelox), ofloxacin (Floxin), gemifloxacin (Factive) and delafloxacin (Baxdela). See FDA’s
to search any fluoroquinolone and access the drug’s complete labeling information.
Fluoroquinolones are an important treatment option for some serious bacterial infections—such as certain types of bacterial
—when the benefits of these drugs outweigh the risks. Therefore, they should remain available as a therapeutic option. FDA remains committed to keeping information about these products current to ensure that health care professionals and patients can make an informed decision about their use.
Debra E. Boxwell, PharmD, is a Safety Evaluator in the FDA’s Office of Surveillance and Epidemiology.